Elahe Bordbar, MD
Neurology · Philadelphia, PANPI 1306374954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 31.8% of the total. 2025 is the largest year on record at $436, 4.8 times the $90 reported in 2022. That places this record below the midpoint for neurology clinicians in PA, where the typical reported total is $778.
Across 44 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$312
- Eisai Inc.$170
- SK Life Science, Inc.$105
- Pfizer$99
- Neurelis, Inc.$68
- UCB, Inc.$57
- plus $171 from 6 others
What the payments were for
- Food & beverage$96899%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $312 |
| Eisai Inc. | 9 | $170 |
| SK Life Science, Inc. | 4 | $105 |
| Pfizer | 4 | $99 |
| Neurelis, Inc. | 4 | $68 |
| UCB, Inc. | 3 | $57 |
| Lilly USA, LLC | 2 | $41 |
| Genentech USA, Inc. | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$981 in reported general payments places this provider in the 50th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $534 |
| Donepezil Hcl | 30 | $375 |
| Memantine Hcl | 17 | $266 |
| Gabapentin | 26 | $206 |
| Atorvastatin Calcium | 14 | $91 |
| Quetiapine Fumarate | 12 | $77 |
| ClopidogrelClopidogrel Bisulfate | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.